Chiasma raises $600.0M (Israel, Sep 2026)
Reach the investors backing rounds like this
Backed by F2, MPM Capital +3 more · verified emails and LinkedIn on Datapile
Israeli startups raised nearly $600m in August - Globes - Israel Business News
Chiasma is a biopharmaceutical company focused on developing oral therapies for rare diseases, specifically acromegaly. The company aims to provide a more patient-friendly alternative to existing injectable treatments, which are often painful and inconvenient. Despite recent setbacks, Chiasma is preparing to submit trial results to the FDA and seeks to launch its product in the near future.
Israeli startups raised nearly $600m in August Globes - Israel Business News
| Sep 18, 2026 | MIND Security | $72.0M | Series B | Israel |
| Sep 15, 2026 | Unknown AI Startup | $31.0M | — | Israel |
| Sep 09, 2026 | Cylake | $245.0M | Convertible Note | Israel |
| Sep 09, 2026 | HydroSight | $5.0M | Seed | Israel |
8,996 investors back startups in Israel
You just read who funded Chiasma. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.